Advice

following a full submission:

tirzepatide (Mounjaro®) is accepted for restricted use within NHSScotland.

Indication under review: For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

SMC restriction: for use in adults with BMI ≥30 kg/m2* and at least one weight-related comorbidity.
*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.

In phase III studies, tirzepatide, as an adjunct to diet and exercise, was associated with significant reduction in body weight compared with placebo in patients with BMI ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition.

Medicine details

Medicine name:
tirzepatide (Mounjaro)
SMC ID:
SMC2653
Indication:

For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of:

  • ≥30 kg/m2 (obesity) or

  • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea [OSA], cardiovascular disease [CVD], prediabetes, or type 2 diabetes mellitus [T2DM])
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Restricted
Date advice published
10 June 2024